BioStock: Idogen's transformation to clinical phase with IDO 8

Recently, the biotech company Idogen received approval from the ethics committee in Oslo for the clinical phase I/IIa study with the cell therapy within the IDO 8 programme in patients with haemophilia A. In addition, the company is preparing to obtain approval to start the study in countries other than Sweden and Norway. BioStock had a chat with Hanjing Xie, CMO, about the study and her time in the company. 

Read the full article at biostock.se:

https://www.biostock.se/en/2022/09/idogens-transformation-to-clinical-phase-with-ido8/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se